- Report
- December 2025
- 150 Pages
Germany
From €4458EUR$4,850USD£3,800GBP
- Report
- November 2025
- 150 Pages
Japan
From €4458EUR$4,850USD£3,800GBP
- Report
- November 2025
- 150 Pages
China
From €4458EUR$4,850USD£3,800GBP
- Report
- September 2025
- 150 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- June 2025
- 150 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- September 2024
- 150 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- April 2025
- 150 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- March 2025
- 150 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- March 2025
- 150 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- October 2025
- 82 Pages
Qatar
From €4137EUR$4,500USD£3,526GBP
- Report
- October 2025
- 90 Pages
Kuwait
From €4137EUR$4,500USD£3,526GBP
- Report
- August 2025
- 50 Pages
Global
From €9188EUR$9,995USD£7,831GBP
- Report
- July 2025
- 250 Pages
Global
From €2389EUR$2,599USD£2,036GBP
- Report
- June 2025
- 77 Pages
Japan
From €2252EUR$2,450USD£1,919GBP
- Report
- August 2024
- 116 Pages
Global
From €4137EUR$4,500USD£3,526GBP
- Report
- August 2023
- 1300 Pages
Global
From €8181EUR$8,900USD£6,973GBP
- Report
- August 2023
- 300 Pages
Middle East, Africa
From €4504EUR$4,900USD£3,839GBP
- Report
- August 2023
- 300 Pages
Latin America
From €4504EUR$4,900USD£3,839GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4504EUR$4,900USD£3,839GBP
- Report
- August 2023
- 300 Pages
Europe
From €4504EUR$4,900USD£3,839GBP

The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more